|
1.
|
|
11 p, 379.4 KB |
Postoperative Chemotherapy Use and Outcomes From ADAURA : Osimertinib as Adjuvant Therapy for Resected EGFR-Mutated NSCLC
/
Wu, Yi-Long (Guangdong Lung Cancer Institute) ;
John, Thomas (Austin Health) ;
Grohe, Christian (Evangelische Lungenklinik) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Goldman, Jonathan W. (University of California) ;
Kim, Sang-We (University of Ulsan) ;
Kato, Terufumi (Kanagawa Cancer Center) ;
Laktionov, Konstantin (Blokhin National Medical Research Center of Oncology) ;
Vu, Huu Vinh (Choray Hospital) ;
Wang, Zhije (Chinese Academy of Medical Sciences) ;
Lu, Shun (Shanghai Jiao Tong University) ;
Lee, Kye Young (Konkuk University Medical Center) ;
Akewanlop, Charuwan (Siriraj Hospital) ;
Yu, Chong-Jen (National Taiwan University College of Medicine) ;
de Marinis, Filippo (European Institute of Oncology) ;
Bonanno, Laura (Istituto Oncologico Veneto) ;
Domine, Manuel (Instituto de Investigación Sanitaria-Fundación Jiménez Díaz) ;
Shepherd, Frances A. (University of Toronto) ;
Zeng, Lingmin (AstraZeneca) ;
Atasoy, Ajlan (AstraZeneca) ;
Herbst, Roy S. (Yale School of Medicine) ;
Tsuboi, Masahiro (National Cancer Center Hospital East) ;
Universitat Autònoma de Barcelona
Introduction: Adjuvant chemotherapy is recommended in patients with resected stages II to IIIA (and select IB) NSCLC; however, recurrence rates are high. In the phase 3 ADAURA study (NCT02511106), osimertinib was found to have a clinically meaningful improvement in disease-free survival (DFS) in patients with resected stages IB to IIIA EGFR-mutated (EGFRm) NSCLC. [...]
2022 -  10.1016/j.jtho.2021.10.014
Journal of Thoracic Oncology, Vol. 17 Núm. 3 (march 2022) , p. 423-433
|
|
|
2.
|
|
17 p, 921.2 KB |
Real-World Validation of Molecular International Prognostic Scoring System for Myelodysplastic Syndromes
/
Sauta, Elisabetta (Humanitas Clinical and Research Center (Itàlia)) ;
Robin, Marie (Department of Hematology and Bone Marrow Transplantation. Hôpital Saint-Louis (França)) ;
Bersanelli, Mateo (Department of Biomedical Sciences. Humanitas University) ;
Travaglino, Erica (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ;
Meggendorfer, Manje (Mll Munich Leukemia Laboratory) ;
Zhao, Lin-Pierre (Department of Hematology and Bone Marrow Transplantation. Hôpital Saint-Louis (França)) ;
Caballero Berrocal, Juan Carlos (Hematology Department. Hospital Universitario de Salamanca) ;
Sala, Claudia (Experimental. Diagnostic and Specialty Medicine. Dimes) ;
Maggioni, Giulia (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ;
Bernardi, Massimo (University Vita-Salute San Raffaele (Itàlia)) ;
Di Grazia, Carmen (Irccs Ospedale Policlinico San Martino) ;
Vago, Luca (University Vita-Salute San Raffaele (Itàlia)) ;
Rivoli, Giulia (Irccs Ospedale Policlinico San Martino) ;
Borin, Lorenza (Ospedale San Gerardo) ;
D'Amico, Saverio (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ;
Tentori, Cristina Astrid (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ;
Ubezio, Marta (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ;
Campagna, Alessia (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ;
Russo, Antonio (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ;
Mannina, Daniele (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ;
Lanino, Luca (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ;
Chiusolo, Patrizia (Università Cattolica Del Sacro Cuore) ;
Giaccone, Luisa (Department of Molecular Biotechnology and Health Sciences. University of Turin) ;
Voso, Maria Teresa (Tor Vergata University) ;
Riva, Maria (Asst Grande Ospedale Metropolitano Niguarda) ;
Oliva, Esther Natalie (Grande Ospedale Metropolitano Bianchi Melacrino Morelli) ;
Zampini, Matteo (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ;
Riva, Elena (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ;
Nibourel, Olivier (Chu Lille) ;
Bicchieri, Marinela (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ;
Bolli, Niccolo (Department of Oncology and Hemato-Oncology. University of Milan) ;
Rambaldi, Alessandro (Azienda Ospedaliera Papa Giovanni Xxiii) ;
Passamonti, Francesco (Department of Medicine and Surgery. University of Insubria) ;
Savevski, Victor (IRCCS Humanitas Clinical and Research Center (Milà, Itàlia)) ;
Santoro, Armando (Department of Biomedical Sciences. Humanitas University) ;
Germing, Ulrich (Department of Hematology. Heinrich-Heine-University. University Clinic) ;
Kordasti, Shahram (Hematology Department. DISCLIMO-Università Politecnica Delle Marche) ;
Santini, Valeria (University of Florence) ;
Diez-Campelo, María (Hospital Universitario de Salamanca) ;
Sanz, Guillermo (Hospital Universitari i Politècnic La Fe (València)) ;
Sole, F (Institut de Recerca Contra la Leucèmia Josep Carreras) ;
Kern, Wolfgang (Mll Munich Leukemia Laboratory) ;
Platzbecker, Uwe (University Hospital Leipzig) ;
Arenillas, Leonor (Department of Hematology and Bone Marrow Transplantation. Hôpital Saint-Louis) ;
Fenaux, Pierre (Department of Hematology and Bone Marrow Transplantation. Hôpital Saint-Louis) ;
Haferlach, Torsten (Mll Munich Leukemia Laboratory) ;
Castellani, Gastone (Experimental. Diagnostic and Specialty Medicine. Dimes) ;
Della Porta, Matteo Giovanni (Department of Biomedical Sciences. Humanitas University)
PURPOSEMyelodysplastic syndromes (MDS) are heterogeneous myeloid neoplasms in which a risk-adapted treatment strategy is needed. Recently, a new clinical-molecular prognostic model, the Molecular International Prognostic Scoring System (IPSS-M) was proposed to improve the prediction of clinical outcome of the currently available tool (Revised International Prognostic Scoring System [IPSS-R]). [...]
2023 - 10.1200/JCO.22.01784
Journal of Clinical Oncology, Vol. 41 Núm. 15 (20 2023) , p. 2827-2842
|
|
|
3.
|
|
13 p, 471.4 KB |
Overall Survival with Daratumumab, Lenalidomide, and Dexamethasone in Previously Treated Multiple Myeloma (POLLUX) : A Randomized, Open-Label, Phase III Trial
/
Dimopoulos, Meletios (National and Kapodistrian University of Athens) ;
Oriol, Albert (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Nahi, Hareth (Department of Medicine. Karolinska University) ;
San-Miguel, J (Clínica Universidad de Navarra) ;
Bahlis, Nizar J. (University of Calgary) ;
Usmani, S. Z (Memorial Sloan Kettering Cancer Center) ;
Rabin, Neil (Department of Haematology. University College London Hospitals NHS Trust) ;
Orlowski, Robert Z. (Department of Lymphoma and Myeloma. The University of Texas) ;
Suzuki, Kenshi (Department of Hematology. Japanese Red Cross Medical Center) ;
Plesner, Torben (University of Southern Denmark) ;
Yoon, Sung Soo (Department of Internal Medicine. Seoul National University) ;
Ben Yehuda, Dina (Hematology Department. Hebrew University) ;
Richardson, Paul G. (Dana-Farber Cancer Institute (Estats Units d'Amèrica)) ;
Goldschmidt, Hartmut (Heidelberg University Hospital (Alemanya)) ;
Reece, Donna (Department of Medical Oncology and Hematology. Princess Margaret Cancer Centre) ;
Ahmadi, Tahamtan (Genmab US (Estats Units d'Amèrica)) ;
Qin, Xiang (Janssen Research & Development (Xina)) ;
Garvin Mayo, Wendy (Janssen Research & Development (Estats Units d'Amèrica)) ;
Gai, Xue (Janssen Research & Development (Estats Units d'Amèrica)) ;
Carey, Jodi (Janssen Research & Development (Estats Units d'Amèrica)) ;
Carson, Robin (Janssen Research & Development (Estats Units d'Amèrica)) ;
Moreau, Philippe (Hematology Department. University Hospital Hôtel-Dieu)
PURPOSEWith the initial analysis of POLLUX at a median follow-up of 13. 5 months, daratumumab in combination with lenalidomide and dexamethasone (D-Rd) significantly prolonged progression-free survival versus lenalidomide and dexamethasone (Rd) alone in patients with relapsed or refractory multiple myeloma (RRMM). [...]
2023 - 10.1200/JCO.22.00940
Journal of Clinical Oncology, Vol. 41 Núm. 8 (october 2023) , p. 1590-1599
|
|
|
4.
|
|
17 p, 1.2 MB |
Impact of Minimal Residual Disease on Progression-Free Survival Outcomes after Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study
/
Munir, Talha (St James's Hospital) ;
Moreno, Carol (Institut Germans Trias i Pujol. Institut de Recerca contra la Leucèmia Josep Carreras) ;
Owen, Carolyn (Tom Baker Cancer Centre) ;
Follows, George (Addenbrookes Hospital (Cambridge, Regne Unit)) ;
Benjamini, Ohad (Sheba Medical Center) ;
Janssens, Ann (UZ Leuven Gasthuisberg) ;
Levin, Mark-David (Albert Schweitzer Hospital) ;
Osterborg, Anders (Karolinska University Hospital and Karolinska Institutet (Suecia)) ;
Robak, Tadeusz (Medical University of Lodz. Copernicus Memorial Hospital) ;
Simkovic, Martin (University Hospital Hradec Kralove (República Txeca)) ;
Stevens, Don (Norton Cancer Institute) ;
Voloshin, Sergey (Russian Scientific and Research Institute of Hematology and Transfusiology) ;
Vorobyev, Vladimir (S.P. Botkin Moscow City Clinical Hospital) ;
Yagci, Munci (Gazi Universitesi Tip Fakultesi) ;
Ysebaert, Loic (Institut Universitaire du Cancer Toulouse Oncopole) ;
Qi, Keqin (Janssen Research & Development) ;
Qi, Qianya (Janssen Research & Development) ;
Parisi, Lori (Janssen Research & Development) ;
Srinivasan, Srinivasan (Oncology Translational Research. Janssen Research & Development) ;
Schuier, Natasha (Janssen Research & Development) ;
Baeten, Kurt (Janssen Research & Development) ;
Howes, Angela (Janssen Research & Development) ;
Caces, Donne Bennett (Janssen Research & Development) ;
Niemann, Carsten U (Rigshospitalet Copenhagen University Hospital) ;
Kater, Arnon P. (Amsterdam Medical Centers. University of Amsterdam)
PURPOSEIn GLOW, fixed-duration ibrutinib + venetoclax showed superior progression-free survival (PFS) versus chlorambucil + obinutuzumab in older/comorbid patients with previously untreated chronic lymphocytic leukemia (CLL). [...]
2023 - 10.1200/JCO.22.02283
Journal of Clinical Oncology, Vol. 41 Núm. 21 (20 2023) , p. 3689-3699
|
|
|
5.
|
|
10 p, 786.4 KB |
Haploidentical transplantation is associated with better overall survival when compared to single cord blood transplantation : An EBMT-Eurocord study of acute leukemia patients conditioned with thiotepa, busulfan, and fludarabine
/
Giannotti, Federica (Saint-Antoine Hospital) ;
Labopin, Myriam (Hôpital Saint-Antoine (Paris, França)) ;
Shouval, Roni (Chaim Sheba Medical Center (Israel)) ;
Sanz, Jaime (Instituto de Salud Carlos III) ;
Arcese, William (Rome Transplant Network tor Vergatä) ;
Angelucci, Emanuele (Ospedale Policlinico San Martino) ;
Malouf Sierra, Jorge 1971- (Institut d'Investigació Biomèdica Sant Pau) ;
Ribera, Jose-Maria (Institut Germans Trias i Pujol. Hospital Universitari Germans Trias i Pujol) ;
Santarone, Stella (Ospedale Civile) ;
Benedetto, Bruno (S.S.C.V.D Trapianto di Cellule Staminali A.O.U Citta della Salute e della Scienza di Torino) ;
Rambaldi, Alessandro (Azienda Ospedaliera Papa Giovanni XXIII) ;
Saccardi, Riccardo (Azienda Ospedaliera Universitaria Careggi) ;
Blaise, Didier (Institut Paoli Calmettes) ;
Carella, Michele Angelo (IRCCS) ;
Rocha, Vanderson (Universidade de São Paulo) ;
Baron, Frederic (University of Liege) ;
Mohty, Mohamad (Hospital Saint- Antoine) ;
Ruggeri, Annalisa (Ospedale Pediatrico Bambino Gesù (Roma, Itàlia)) ;
Nagler, Arnon (Tel-Aviv University) ;
Universitat Autònoma de Barcelona
Thiotepa-busulfan-fludarabine (TBF) is a widely used conditioning regimen in single umbilical cord blood transplantation (SUCBT). More recently, it was introduced in the setting of non-T cell depleted haploidentical stem cell transplantation (NTD-Haplo). [...]
2018 - 10.1186/s13045-018-0655-8
Journal of hematology & oncology, Vol. 11 Núm. 1 (30 2018) , p. 110
|
|
|
6.
|
|
9 p, 707.5 KB |
Compliance and Outcome of Elderly Patients Treated in the Concurrent Once-Daily Versus Twice-Daily Radiotherapy (CONVERT) Trial
/
Christodoulou, M. (The Christie NHS Foundation Trust) ;
Blackhall, Fiona (University of Manchester) ;
Mistry, H. (University of Manchester) ;
Leylek, A. (CancerCare Manitoba) ;
Knegjens, J. (The Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital) ;
Remouchamps, V. (CHU UCL Namur. site Ste Elisabeth) ;
Martel-Lafay, I. (Centre Léon Bérard) ;
Farré, Núria (Institut d'Investigació Biomèdica Sant Pau) ;
Zwitter, M. (Institute of Oncology) ;
Lerouge, D. (Centre François Baclesse (Caen, França)) ;
Pourel, N. (Institut Sainte-Catherine) ;
Janicot, H. (CHU Gabriel Montpied) ;
Scherpereel, A. (Hospital of the University (CHRU) of Lille) ;
Tissing-Tan, C. (Radiotherapiegroep) ;
Peignaux, K. (Georges Francois LECLERC Center) ;
Geets, X. (Cliniques universitaires Saint-Luc. MIRO-IREC-UCL) ;
Konopa, K. (Medical University of Gdansk) ;
Faivre-Finn, C. (University of Manchester)
There is a lack of data on the efficacy and safety of concurrent chemoradiotherapy in elderly, limited-stage, patients with SCLC. We compared outcomes of patients 70 years of age or older versus younger patients within the Concurrent Once-daily Versus twice-daily RadioTherapy (CONVERT) trial. [...]
2019 - 10.1016/j.jtho.2018.09.027
Journal of Thoracic Oncology, Vol. 14 Núm. 1 (january 2019) , p. 63-71
|
|
|
7.
|
|
11 p, 893.9 KB |
SARS-CoV-2 vaccine response and rate of breakthrough infection in patients with hematological disorders
/
Piñana, José Luis (Fundación INCLIVA. Instituto de Investigación Sanitaria Hospital Clínico Universitario de Valencia) ;
López-Corral, Lucía (Hospital Clínico Universitario (Salamanca)) ;
Martino Bofarull, Rodrigo (Institut d'Investigació Biomèdica Sant Pau) ;
Vazquez, Lourdes (Hospital Clínico Universitario (Salamanca)) ;
Pérez, Ariadna (Fundación INCLIVA. Instituto de Investigación Sanitaria Hospital Clínico Universitario de Valencia) ;
Martin-Martin, Gabriel Andres (Hospital Clínico Universitario (Salamanca)) ;
Gago, Beatriz (Hospital Regional Universitario Carlos Haya (Málaga)) ;
Sanz-Linares, Gabriela (Institut Català Oncologia-Hospital Duran i Reynals. Institut d'Investigació Biomèdica de Bellvitge) ;
Sánchez Salinas, Andrés (Hospital Clínico Universitario Virgen de la Arrixaca (El Palmar, Múrcia)) ;
Villalon, Lucia B. (Hospital Universitario Fundación Alcorcón) ;
Conesa-García, Venancio (Hospital General Universitario de Elche) ;
Olave, María Teresa (Hospital Clínico Universitario Lozano Blesa. Instituto de Investigacón Sanitaria Aragón) ;
Corona de Lapuerta, Magdalena (Hospital Universitario Ramón y Cajal (Madrid)) ;
Marcos-Corrales, Sara (Hospital Clínico Universitario (Salamanca)) ;
Tormo, Mar (Instituto de Investigación Sanitaria Fundación Para la Investigación del Hospital Clínico de Valencia) ;
Hernandez-Rivas, JA (Hospital Universitario Infanta Leonor) ;
Montoro, Juan B. (Hospital Universitari y politècnic La Fe (València)) ;
Rodríguez-Fernández, Alicia (Hospital Universitario Virgen Macarena (Sevilla, Andalusia)) ;
Risco-Gálvez, Irene (Hospital Arnau de Vilanova (València)) ;
Rodríguez-Belenguer, Pablo (Research Program on Biomedical Informatics (GRIB). Institut Hospital del Mar d'Investigacions Mèdiques. Universitat Pompeu Fabra) ;
Hernandez-Boluda, Juan Carlos (Hospital Clínic Universitari (València)) ;
Garcia Cadenas, Irene (Institut d'Investigació Biomèdica Sant Pau) ;
Ruíz-García, Montserrat M. (Hospital General Universitario de Elche) ;
Muñoz-Bellido, Juan Luis (Hospital Clínico Universitario (Salamanca)) ;
Solano, Carlos (Hospital Clínic Universitari (València)) ;
Cedillo Cedillo, Angel (Hematopoietic Stem Cell Transplantation and Cell Therapy Group) ;
Sureda, Anna (Institut Català Oncologia-Hospital Duran i Reynals. Institut d'Investigació Biomèdica de Bellvitge) ;
Navarro, David (Hospital Clínic Universitari (València))
Background: The clinical efficacy of SARS-CoV-2 vaccines according to antibody response in immunosuppressed patients such as hematological patients has not yet been established. Patients and methods: A prospective multicenter registry-based cohort study conducted from December 2020 to December 2021 by the Spanish transplant and cell therapy group was used to analyze the relationship of antibody response at 3-6 weeks after full vaccination (2 doses) with breakthrough SARS-CoV-2 infection in 1394 patients with hematological disorders. [...]
2022 - 10.1186/s13045-022-01275-7
Journal of hematology & oncology, Vol. 15 Núm. 1 (december 2022) , p. 54
|
|
|
8.
|
|
14 p, 425.7 KB |
Randomized Phase II Study of Paclitaxel plus Alisertib versus Paclitaxel plus Placebo as Second-Line Therapy for SCLC : Primary and Correlative Biomarker Analyses
/
Owonikoko, Taofeek K. (Winship Cancer Institute of Emory University) ;
Niu, Huifeng (Millennium Pharmaceuticals. Inc.) ;
Nackaerts, Kristiaan (KU Leuven. Universitaire Ziekenhuizen) ;
Csoszi, Tibor (Hetenyi G Korhaz) ;
Ostoros, Gyula (Orszagos Koranyi TBC es Pulmonologiai Intezet) ;
Mark, Zsuzsanna (Tudogyogyintezet Torokbalint) ;
Baik, Christina (University of Washington Seattle Cancer Care Alliance) ;
Joy, Anil Abraham (University of Alberta. Cross Cancer Institute) ;
Chouaid, Christos (CHI de Créteil) ;
Jaime, Jesus Corral (Hospital Universitario Virgen del Rocío (Sevilla, Andalusia)) ;
Kolek, Vitezslav (Fakultni Nemocnice Olomouc) ;
Majem, Margarita (Institut d'Investigació Biomèdica Sant Pau) ;
Roubec, Jaromir (Fakultni Nemocnice Ostrava) ;
Santos, Edgardo S. (Lynn Cancer Institute/Boca Raton Regional Hospital) ;
Chiang, Anne C. (Yale University School of Medicine) ;
Speranza, Giovanna (Université de Sherbrooke) ;
Belani, Chandra P. (Penn State Cancer Institute) ;
Chiappori, Alberto (H. Lee Moffitt Cancer Center) ;
Patel, Manish R. (Florida Cancer Specialists/Sarah Cannon Research Institute) ;
Czebe, Krisztina (Tudogyogyintezet Torokbalint) ;
Byers, Lauren (Tudogyogyintezet Torokbalint) ;
Bahamon, Brittany (Millennium Pharmaceuticals. Inc.) ;
Li, Cong (Millennium Pharmaceuticals. Inc.) ;
Sheldon-Waniga, Emily (Millennium Pharmaceuticals. Inc.) ;
Kong, Eric F. (University of Texas M. D. Anderson Cancer Center) ;
Williams, Miguel (Millennium Pharmaceuticals. Inc.) ;
Badola, Sunita (Millennium Pharmaceuticals. Inc.) ;
Shin, Hyunjin (Millennium Pharmaceuticals. Inc.) ;
Bedford, Lisa (Millennium Pharmaceuticals. Inc.) ;
Ecsedy, Jeffrey A. (Millennium Pharmaceuticals. Inc.) ;
Bryant, Matthew (University of Texas M. D. Anderson Cancer Center) ;
Jones, Sian (University of Texas M. D. Anderson Cancer Center) ;
Simmons, John (University of Texas M. D. Anderson Cancer Center) ;
Leonard, E. Jane (Millennium Pharmaceuticals. Inc.) ;
Ullmann, Claudio Dansky (Millennium Pharmaceuticals. Inc.) ;
Spigel, David R. (Personal Genome Diagnostics) ;
Universitat Autònoma de Barcelona
We assessed the Aurora A kinase inhibitor, alisertib, plus paclitaxel (henceforth referred to as alisertib/paclitaxel) as second-line treatment for SCLC. In this double-blind study, patients with relapsed or refractory SCLC were stratified by relapse type (sensitive versus resistant or refractory) and brain metastases and randomized 1:1 to alisertib/paclitaxel or placebo plus paclitaxel (henceforth referred to as placebo/paclitaxel) in 28-day cycles. [...]
2020 - 10.1016/j.jtho.2019.10.013
Journal of Thoracic Oncology, Vol. 15 Núm. 2 (february 2020) , p. 274-287
|
|
|
9.
|
|
7 p, 442.8 KB |
Treatment decision-making in chronic lymphocytic leukaemia : Key factors for healthcare professionals. PRELIC study
/
Boque, Concepcion (Institut Català d'Oncologia) ;
Abad, María Reyes (Hospital Universitario Miguel Servet (Saragossa)) ;
Agustin Ferrandez, Maria Jose (Hospital Universitario Miguel Servet (Saragossa)) ;
García-Goñi, Manuel (Universidad Complutense de Madrid) ;
Moreno, Carolina M. (Institut d'Investigació Biomèdica Sant Pau) ;
Gabás-Rivera, Clara (Outcomes 10) ;
Granados, Enrique (Gilead Sciences) ;
Castro-Gómez, Antonio (Gilead Sciences) ;
Pardo, Carlos (Gilead Sciences) ;
Lizán, Luis (Universitat Jaume I)
To explore the preferences of Spanish healthcare professionals (haematologists and hospital pharmacists) for the treatment selection of active Chronic Lymphocytic Leukaemia (CLL) patients at first relapse, condition that mainly afflicts older adults. [...]
2020 - 10.1016/j.jgo.2019.03.010
Journal of Geriatric Oncology, Vol. 11 Núm. 1 (january 2020) , p. 24-30
|
|
|
10.
|
|
14 p, 2.0 MB |
Effect of tumor burden and radical surgery on survival difference between upfront, early interval or delayed cytoreductive surgery in ovarian cancer
/
Angeles, Martina Aida (Institut Universitaire du Cancer de Toulouse Oncopole) ;
Cabarrou, Bastien (Institut Universitaire du Cancer de Toulouse Oncopole) ;
Gil-Moreno, Antonio 1965- (Vall d'Hebron Institut d'Oncologia) ;
Pérez-Benavente, Assumpció (Vall d'Hebron Institut d'Oncologia) ;
Spagnolo, Emanuela (Hospital Universitario La Paz (Madrid)) ;
Rychlik, Agnieszka (Department of Gynaecologic Oncology, Maria Skłodowska-Curie National Research Institute of Oncology) ;
Martínez-Gómez, Carlos (INSERM CRCT 1 (França)) ;
Guyon, Frédéric (Department of Surgical Oncology, Institut Bergonié (França)) ;
Zapardiel, Ignacio (Hospital Universitario La Paz (Madrid)) ;
Querleu, Denis (Honorary Professor of the University of Toulouse) ;
Illac, Claire (Institut Universitaire du Cancer de Toulouse Oncopole) ;
Migliorelli, Federico (Department of Gynaecology and Obstetrics, Centre Hospitalier Intercommunal des Vallées de l'Ariège (França)) ;
Bétrian, Sarah (Institut Universitaire du Cancer de Toulouse Oncopole) ;
Ferron, Gwénaël (INSERM CRCT 19 (França)) ;
Hernández Gutierrez, Alicia (Instituto de Investigación Sanitaria del Hospital Universitario La Paz) ;
Martinez, Alejandra (INSERM CRCT 19 (França)) ;
Universitat Autònoma de Barcelona
We sought to evaluate the impact on survival of tumor burden and surgical complexity in relation to the number of cycles of neoadjuvant chemotherapy (NACT) in patients with advanced ovarian cancer (OC) with minimal (CC-1) or no residual disease (CC-0). [...]
2021 - 10.3802/jgo.2021.32.e78
Journal of Gynecologic Oncology, Vol. 32 (august 2021)
|
|
visitant ::
identificació
alerta personal via correu electrònic o subscribiu-vos al 
canal RSS.
